Over 14% of US adolescents reported a major depressive episode last year. This article details its prevalence, key risk factors, and the significant treatment gap.
Key Takeaways
- 14.3% of US adolescents aged 12–17 reported having at least one major depressive episode (MDE) in the past year
- 5.7% of US adolescents aged 12–17 had a MDE with severe impairment in the past year
- 8.3% of US adolescents aged 12–17 reported experiencing persistent depressive disorder symptoms (dysthymia) in the past year
- In the US, 21% of students reported that they experienced homelessness at some point (risk correlates with depression)
- Homeless youth are 2.6 times more likely to have major depressive episodes than housed youth (US study estimate)
- Parental incarceration is associated with a 2-fold increase in mental health problems in adolescents (meta-analytic estimate)
- Among US adolescents, 15.3% reported they had poor access to mental health services (barrier correlates with untreated depression)
- 9.1% of US adolescents reported delaying or not getting mental health care because of cost (barrier estimate)
- Among adolescents with depression, only about 40% receive treatment (treatment gap estimate in US context)
- In the US, the number of adolescent mental health visits to emergency departments increased from 2013 to 2019 (trend, emergency department utilization)
- In the US, 18% of high school students reported that they felt persistently sad or hopeless in 2019 (YRBS estimate)
- In the US, 19% of high school students reported that they seriously considered suicide in 2019 (YRBS estimate)
- Interpersonal psychotherapy (IPT) for depressed adolescents shows significant symptom reduction versus control groups in randomized trials (systematic review estimate)
- A meta-analysis found antidepressant medications reduced depressive symptoms in adolescents with a standardized mean difference around -0.3 to -0.4 versus placebo (effect estimate)
- In the FDA evidence review for antidepressants in major depressive disorder, response rates favored antidepressant over placebo by small margins (trial outcome pattern)
About 1 in 7 US teens reported a major depressive episode in the past year.
Related reading
01 · Category
Prevalence Rates22 stats
01
14.3% of US adolescents aged 12–17 reported having at least one major depressive episode (MDE) in the past year
02
5.7% of US adolescents aged 12–17 had a MDE with severe impairment in the past year
03
8.3% of US adolescents aged 12–17 reported experiencing persistent depressive disorder symptoms (dysthymia) in the past year
04
11.0% of US adolescents aged 12–17 reported having any major depressive episode in the past year, per National Survey on Drug Use and Health (NSDUH)
05
8.0% of adolescents aged 12–17 reported having depression symptoms that caused serious impairment in the past year
06
50% of lifetime mental disorders begin by age 14
07
20% of adolescents worldwide experience a mental health condition
08
3.1% of adolescents globally had depressive disorder in 2015 (age 10–19)
09
5.0% of adolescents globally had depressive disorder in 2015 (age 10–19, females higher)
10
2.0% of adolescents globally had depressive disorder in 2015 (age 10–19, males lower)
11
4.1% of adolescents globally had depressive disorder in 2019 (age 10–19)
12
6.1% of young people aged 12–17 in Great Britain had a probable depressive disorder (based on self-report screening surveys)
13
14.0% of students aged 13–17 in England reported depressive symptoms (self-reported questionnaire-based estimates)
14
3.6% of youth in the US aged 12–17 had a substance use disorder plus major depression (co-occurrence estimate)
15
6.8% of adolescents aged 12–17 with a past-year MDE reported that they attempted suicide
16
23% of adolescents with depression symptoms experience persistent symptoms beyond 2 years (longitudinal pattern estimate)
17
28% of adolescents with depression had recurrence or chronicity within 5 years (longitudinal cohort estimate)
18
Depression affects about 11% of adolescents aged 12–17 years in the US (self-reported, past year)
19
Depression accounts for 5.6% of total global disability-adjusted life years (DALYs) among adolescents (10–14 and 15–19 combined)
20
In the US, 8.7% of adolescents aged 12–17 experienced MDE in 2014 (NSDUH estimate)
21
In the US, 9.7% of adolescents aged 12–17 experienced MDE in 2016 (NSDUH estimate)
22
In the US, 10.8% of adolescents aged 12–17 experienced MDE in 2018 (NSDUH estimate)
Interpretation
Prevalence Rates Interpretation
About 11% of US adolescents aged 12–17 reported a major depressive episode in the past year, and the estimate rose from 8.7% in 2014 to 10.8% in 2018, showing a clear upward trend.
02 · Category
Risk Factors14 stats
01
In the US, 21% of students reported that they experienced homelessness at some point (risk correlates with depression)
02
Homeless youth are 2.6 times more likely to have major depressive episodes than housed youth (US study estimate)
03
Parental incarceration is associated with a 2-fold increase in mental health problems in adolescents (meta-analytic estimate)
04
Adverse Childhood Experiences (ACEs) show a graded relationship: adolescents with 4+ ACEs have higher odds of depression (US ACE study pattern)
05
In US data, 13% of adolescents reported 4+ ACEs (which elevates depression risk)
06
Among US adolescents with 4+ ACEs, the odds of depression are about 4.5 times those with no ACEs (risk gradient estimate)
07
Low socioeconomic status is associated with higher depression prevalence in adolescents (meta-analytic estimate)
08
Adolescent sleep duration below 6 hours is associated with about a 1.5x higher risk of depression symptoms (systematic review estimate)
09
Adolescents with sleep problems report higher rates of depressive symptoms, with effect sizes in the small-to-moderate range (systematic review estimate)
10
Physical inactivity is linked to a higher likelihood of depression symptoms; adolescents in inactive groups show elevated risk (meta-analysis estimate)
11
Exercise interventions reduce depressive symptoms in youth with moderate effect sizes (meta-analysis estimate)
12
Chronic illness in youth increases the risk of depression symptoms; pooled prevalence is higher than in healthy peers (systematic review estimate)
13
Adolescents with type 1 diabetes have higher rates of depressive symptoms; prevalence estimates exceed 20% in some studies (systematic review estimate)
14
A large share of adolescents with chronic conditions report mental health impacts; anxiety/depression symptoms are common (global systematic review estimate)
Interpretation
Risk Factors Interpretation
Across these studies, depression risk rises sharply with adversity and health barriers, for example teens reporting 4 or more adverse childhood experiences have about 4.5 times the odds of depression, and homeless youth are 2.6 times more likely to experience major depressive episodes than their housed peers.
03 · Category
Service Use17 stats
01
Among US adolescents, 15.3% reported they had poor access to mental health services (barrier correlates with untreated depression)
02
9.1% of US adolescents reported delaying or not getting mental health care because of cost (barrier estimate)
03
Among adolescents with depression, only about 40% receive treatment (treatment gap estimate in US context)
04
In the US, 8.7% of adolescents used mental health services in the past year (NSCH/other national estimate)
05
In the US, 10.9% of adolescents received counseling or therapy for mental health in the past year (survey estimate)
06
In the US, 3.7% of adolescents took prescription medication for mental health in the past year (survey estimate)
07
44% of parents reported that their child did not receive needed mental health services (barrier/treatment gap estimate)
08
During 2020–2021, 1 in 5 US youth experienced an unmet need for mental health care (unmet need estimate)
09
In 2021, 13.5% of US adults reported receiving treatment for depression (adult context but treatment patterns relevant to youth access research)
10
In Australia, 14.3% of young people aged 15–24 reported using psychological services in the past year (service use estimate)
11
In Australia, 17.4% of young people aged 15–24 reported unmet need for psychological services (unmet need estimate)
12
In Germany, only about 35% of adolescents with depressive symptoms receive professional help (survey-based estimate)
13
In the US, 62% of adolescents with depression symptoms report not receiving adequate mental health care (treatment adequacy estimate)
14
In the US, 56% of youth with mental health needs did not receive care at all (survey estimate)
15
In the US, 8.3% of adolescents reported using school counseling services for mental health (survey estimate)
16
In the US, 5.0% of adolescents reported using private counseling or therapy services (survey estimate)
17
In the US, 1 in 6 teens who needed mental health services could not get them because of shortage of providers (barrier estimate)
Interpretation
Service Use Interpretation
Across these data, the treatment gap is striking because only about 40% of depressed teens get care and in the US as many as 56% of youth with mental health needs receive no care at all, with provider shortages also preventing 1 in 6 teens who need services from getting them.
More related reading
04 · Category
Industry Trends13 stats
01
In the US, the number of adolescent mental health visits to emergency departments increased from 2013 to 2019 (trend, emergency department utilization)
02
In the US, 18% of high school students reported that they felt persistently sad or hopeless in 2019 (YRBS estimate)
03
In the US, 19% of high school students reported that they seriously considered suicide in 2019 (YRBS estimate)
04
In the US, 9% of high school students reported making a suicide plan in 2019 (YRBS estimate)
05
In the US, 7% of high school students reported a suicide attempt in 2019 (YRBS estimate)
06
In 2019, 57% of adolescents with major depression did not receive treatment in the past year (treatment gap estimate based on NCS-A/NHIS-style synthesis)
07
In the US, past-year mental health service use among adolescents increased between 2007 and 2017 from 7.9% to 10.1% (trend estimate)
08
Globally, depression is estimated to have increased as a share of disability burdens over recent decades (IHME/GBD trend)
09
In 2019, depressive disorders accounted for about 40.1 million disability-adjusted life years (DALYs) among adolescents 10–14 and 15–19 combined (GBD estimate)
10
In 2019, depressive disorders accounted for about 5.4 million deaths worldwide attributable to depressive disorders (GBD estimate; note: deaths in GBD are indirect/linked to disorder)
11
From 2010 to 2019, global YLDs for depressive disorders increased for adolescents (GBD trend)
12
In 2021, 60% of adolescents reported that anxiety and depression are major concerns (global youth wellbeing survey estimate)
13
In 2022, 66% of adolescents reported that mental health affects their daily life (survey estimate)
Interpretation
Industry Trends Interpretation
In the US, 18% of high school students reported feeling persistently sad or hopeless in 2019 and 57% of adolescents with major depression went without treatment in the past year, even as emergency department visits rose from 2013 to 2019 and past-year mental health service use increased from 7.9% in 2007 to 10.1% in 2017.
05 · Category
Treatment Outcomes21 stats
01
Interpersonal psychotherapy (IPT) for depressed adolescents shows significant symptom reduction versus control groups in randomized trials (systematic review estimate)
02
A meta-analysis found antidepressant medications reduced depressive symptoms in adolescents with a standardized mean difference around -0.3 to -0.4 versus placebo (effect estimate)
03
In the FDA evidence review for antidepressants in major depressive disorder, response rates favored antidepressant over placebo by small margins (trial outcome pattern)
04
In the Treatment for Adolescents with Depression Study (TADS), combined fluoxetine + CBT produced the highest response rates compared with other arms
05
In TADS, 71% of adolescents receiving fluoxetine plus CBT were responders at 12 weeks (trial outcome)
06
In TADS, 35% of adolescents receiving placebo were responders at 12 weeks (trial outcome)
07
In TADS, remission rate was 37% for fluoxetine + CBT at 12 weeks (trial outcome)
08
In TADS, remission rate was 20% for placebo at 12 weeks (trial outcome)
09
Family-based therapy for adolescent depression can reduce symptoms with moderate effect sizes (meta-analysis estimate)
10
Mindfulness-based cognitive therapy (MBCT) for adolescents shows reductions in depressive symptoms compared to controls in controlled trials (meta-analysis estimate)
11
Behavioral activation in adolescents with depression reduces symptoms; pooled effect sizes are moderate (systematic review estimate)
12
In a trial of internet-based CBT, depressive symptoms improved with effect sizes around 0.3–0.5 compared to control (meta-analysis estimate)
13
FDA labeling indicates that pooled pediatric antidepressant trials showed suicidal thinking/behavior of 4% on antidepressants vs 2% on placebo (risk estimate)
14
In those antidepressant trials, the difference corresponded to increased risk and need for close monitoring (quantified warning)
15
In ketamine trials for adolescents are limited; however clinical studies report rapid reduction in depressive symptoms within days in treatment-resistant populations (evidence synthesis with effect sizes)
16
Electroconvulsive therapy (ECT) is effective for severe depression with high remission rates in general adolescent/young populations (systematic review estimate)
17
For adolescents treated with antidepressants, symptom improvement typically begins within 2–4 weeks in many trials (clinical trial timelines synthesis)
18
In TADS, differences in depression scores favored active treatment arms over placebo by around 6–12 weeks (trial outcome timeline)
19
A meta-analysis found that for CBT, dropout rates were similar to control groups (acceptability/safety outcome)
20
In TADS, adverse events rates were similar across some treatment arms, but fluoxetine had known side effects; overall tolerability was reported (trial safety outcomes)
21
In adolescents who receive evidence-based psychotherapy, symptom reduction can be maintained for months after treatment in follow-up studies (maintenance estimate)
Interpretation
Treatment Outcomes Interpretation
Across major adolescent depression treatments, the biggest clear advantage appears in TADS where 71% of teens taking fluoxetine plus CBT were responders at 12 weeks versus 35% on placebo, while remission was 37% versus 20%.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Priyanka Sharma. (2026, February 13). Depression In Teens Statistics. Gitnux. https://gitnux.org/depression-in-teens-statistics
MLA
Priyanka Sharma. "Depression In Teens Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/depression-in-teens-statistics.
Chicago
Priyanka Sharma. 2026. "Depression In Teens Statistics." Gitnux. https://gitnux.org/depression-in-teens-statistics.
Sources & references
47 datasets cited across this report · attribution is report-level
+33 additional datasets cited (not shown individually)